Stanniocalcin2, A Promising New Target for Identifying Patients with Stroke/Ictus

Area of Science:

• Biochemistry
• Hematology
• Cardiovascular Research

Background:

• Calcium (Ca²⁺) homeostasis is vital for platelet function and implicated in thrombotic disorders.
• Reduced stanniocalcin 2 (STC2) expression is linked to prothrombotic conditions in diabetes mellitus type 2 (DM2).

Purpose of the Study:

• To investigate the association between stanniocalcin (STC) expression and thrombotic events in humans.
• To explore STC2 as a potential biomarker for stroke/ictus.

Main Methods:

• Western blotting (WB) to determine STC expression.
• Immunoprecipitation (IP) for protein interaction and phosphorylation analysis.
• Analysis of STC2 expression in platelets of stroke patients and correlation with clinical data.

Main Results:

• Stroke patients exhibited significantly reduced STC2 expression in platelets, particularly younger individuals.
• Acetyl-salicylic acid (ASA) administration normalized STC2 expression in patients without recurrent thrombotic events.
• Increased STC2 phosphorylation suggests enhanced STC2 activity in thrombotic patients.
• Over-activated store-operated calcium entry (SOCE) and altered expression of non-capacitative calcium channels (Orai3, TRPC6) were observed in stroke patients.

Conclusions:

• STC2 plays a role in regulating calcium homeostasis and platelet activation in thrombotic conditions.
• Reduced STC2 expression and altered calcium channel activity are associated with stroke.
• STC2 is a potential diagnostic marker for stroke/ictus in thrombotic patients.